scholarly journals Comprehensive molecular cytogenetic characterization of cervical cancer cell lines

2003 ◽  
Vol 36 (3) ◽  
pp. 233-241 ◽  
Author(s):  
Charles P. Harris ◽  
Xin Yan Lu ◽  
Gopeshwar Narayan ◽  
Bhuvanesh Singh ◽  
Vundavalli V. V. S. Murty ◽  
...  
2018 ◽  
Vol 63 (4) ◽  
pp. 243-255 ◽  
Author(s):  
Ralf Steinacker ◽  
◽  
Thomas Liehr ◽  
Nadezda Kosyakova ◽  
Martina Rincic ◽  
...  

2009 ◽  
pp. NA-NA ◽  
Author(s):  
Turid Knutsen ◽  
Hesed M. Padilla-Nash ◽  
Danny Wangsa ◽  
Linda Barenboim-Stapleton ◽  
Jordi Camps ◽  
...  

OBM Genetics ◽  
2018 ◽  
Vol 2 (3) ◽  
pp. 1-1 ◽  
Author(s):  
Hans Rhode ◽  
◽  
Thomas Liehr ◽  
Nadezda Kosyakova ◽  
Martina Rinčić ◽  
...  

2007 ◽  
Vol 118 (2-4) ◽  
pp. 148-156 ◽  
Author(s):  
C.A. Griffin ◽  
L. Morsberger ◽  
A.L. Hawkins ◽  
M. Haddadin ◽  
A. Patel ◽  
...  

2014 ◽  
Vol 28 (12) ◽  
pp. 884-891 ◽  
Author(s):  
Irma Rojas-Oviedo ◽  
Carlos Camacho-Camacho ◽  
Luis Sánchez-Sánchez ◽  
Jorge Cárdenas ◽  
Hugo López-Muñoz ◽  
...  

2005 ◽  
Vol 97 (1) ◽  
pp. 142-150 ◽  
Author(s):  
Todd D. Tillmanns ◽  
Scott A. Kamelle ◽  
Suresh Guruswamy ◽  
Natalie S. Gould ◽  
Teresa L. Rutledge ◽  
...  

Cancers ◽  
2020 ◽  
Vol 12 (7) ◽  
pp. 1934 ◽  
Author(s):  
Eric Ehrke-Schulz ◽  
Sonja Heinemann ◽  
Lukas Schulte ◽  
Maren Schiwon ◽  
Anja Ehrhardt

Human papillomaviruses (HPV) cause malignant epithelial cancers including cervical carcinoma, non-melanoma skin and head and neck cancer. They drive tumor development through the expression of their oncoproteins E6 and E7. Designer nucleases were shown to be efficient to specifically destroy HPV16 and HPV18 oncogenes to induce cell cycle arrest and apoptosis. Here, we used high-capacity adenoviral vectors (HCAdVs) expressing the complete CRISPR/Cas9 machinery specific for HPV18-E6 or HPV16-E6. Cervical cancer cell lines SiHa and CaSki containing HPV16 and HeLa cells containing HPV18 genomes integrated into the cellular genome, as well as HPV-negative cancer cells were transduced with HPV-type-specific CRISPR-HCAdV. Upon adenoviral delivery, the expression of HPV-type-specific CRISPR/Cas9 resulted in decreased cell viability of HPV-positive cervical cancer cell lines, whereas HPV-negative cells were unaffected. Transduced cervical cancer cells showed increased apoptosis induction and decreased proliferation compared to untreated or HPV negative control cells. This suggests that HCAdV can serve as HPV-specific cancer gene therapeutic agents when armed with HPV-type-specific CRISPR/Cas9. Based on the versatility of the CRISPR/Cas9 system, we anticipate that our approach can contribute to personalized treatment options specific for the respective HPV type present in each individual tumor.


Sign in / Sign up

Export Citation Format

Share Document